NASHVILLE, Tenn. / Mar 05, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 19, 2024, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Wednesday, March 20, 2024, to discuss the results and provide a business update.
Conference Call Details: |
|
Date: | Wednesday, March 20, 2024 |
Time: | 8:00 a.m. Eastern time |
Participant Dial-in: | 1-833-953-2434 (U.S.) |
Replay Dial-in (Passcode 6766979): (telephonic replay through March 27, 2024) | 1-877-344-7529 (U.S.) |
Webcast: (online replay through March 20, 2025) |
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
| Last Trade: | US$38.52 |
| Daily Change: | -0.52 -1.33 |
| Daily Volume: | 523,939 |
| Market Cap: | US$1.430B |
October 06, 2025 September 26, 2025 September 08, 2025 August 11, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
